Jenny Stanton
About Jenny Stanton
Jenny Stanton serves as the Executive Director of Clinical Development at AlloVir, bringing extensive experience from her previous roles at Gilead Sciences and Novartis in clinical research and drug development.
Current Role at AlloVir
Jenny Stanton serves as the Executive Director of Clinical Development at AlloVir, a position she has held since 2021. In this role, she is responsible for overseeing clinical development strategies and ensuring the successful execution of clinical trials. Her work focuses on advancing therapeutic options for patients with viral infections.
Previous Experience at Gilead Sciences
Prior to her current role, Stanton worked at Gilead Sciences in various capacities. She served as Senior Director of Clinical Research from 2018 to 2021, where she led clinical research initiatives. Before that, she was Associate Director of Clinical Research from 2013 to 2018, contributing to the development of clinical programs. Her tenure at Gilead also included a brief role as Executive Director of Clinical Research in 2021 and as a Senior Clinical Research Scientist from 2011 to 2013.
Experience at Novartis
Stanton began her career in clinical research at Novartis, where she worked as a Clinical Trial Leader II from 2007 to 2011. During her time at Novartis, she managed clinical trials and collaborated with cross-functional teams to support drug development efforts.
Educational Background
Stanton has a strong academic background in pharmaceutical sciences. She completed her Pharm.D. at SUNY Buffalo, where she studied Pharmacy from 2002 to 2006. She also participated in the SUNY Buffalo/Novartis Fellowship, achieving a Post-Doc Fellowship in Drug Development from 2006 to 2008. Earlier, she earned a BSc in Chemistry/Biochemistry from Sonoma State University from 1994 to 1998.